US 9,447,180 B2 · Methods of treating a tauopathy

Abstract

The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.

Claims27

Dependent claims

An isolated nucleic acid comprising a nucleotide sequence encoding light chain variable region complementarity-determining regions (CDRs) 1, 2, and 3 of a humanized antibody that specifically binds an epitope within the N-terminal portion of a human Tau polypeptide, wherein the:

(i) VLCDR1 comprises the amino acid sequence of SEQ ID NO:1;
(ii) VLCDR2 comprises the amino acid sequence of SEQ ID NO:2;
and
(iii) VLCDR3 comprises the amino acid sequence of SEQ ID NO:3.

1 more element

An isolated nucleic acid comprising a nucleotide sequence encoding a VH variant and/or a Vk variant, wherein:

a) the VH variant comprises the amino acid sequence depicted in FIG. 9 (SEQ ID NO:36) and/or the Vk variant comprises the amino acid sequence depicted in FIG. 13 (SEQ ID NO:40);
b) the VH variant comprises the amino acid sequence depicted in FIG. 9 (SEQ ID NO:36);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 14 (SEQ ID NO:41);
c) the VH variant comprises the amino acid sequence depicted in FIG. 9 (SEQ ID NO:36);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 15 (SEQ ID NO:42);
d) the VH variant comprises the amino acid sequence depicted in FIG. 9 (SEQ ID NO:36);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 16 (SEQ ID NO:43);
e) the VH variant comprises the amino acid sequence depicted in FIG. 10 (SEQ ID NO:37);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 13 (SEQ ID NO:40);
f) the VH variant comprises the amino acid sequence depicted in FIG. 10 (SEQ ID NO:37);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 14 (SEQ ID NO:41);
g) the VH variant comprises the amino acid sequence depicted in FIG. 10 (SEQ ID NO:37);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 15 (SEQ ID NO:42);
h) the VH variant comprises the amino acid sequence depicted in FIG. 10 (SEQ ID NO:37);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 16 (SEQ ID NO:43);
i) the VH variant comprises the amino acid sequence depicted in FIG. 11 (SEQ ID NO:38);
and/or the Vk variant comprising the amino acid sequence depicted in FIG. 13 (SEQ ID NO:40);
j) the VH variant comprises the amino acid sequence depicted in FIG. 11 (SEQ ID NO:38);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 14 (SEQ ID NO:41);
k) the VH variant comprises the amino acid sequence depicted in FIG. 11 (SEQ ID NO:38);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 15 (SEQ ID NO:42);
l) the VH variant comprises the amino acid sequence depicted in FIG. 11 (SEQ ID NO:38);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 16 (SEQ ID NO:43);
m) the VH variant comprises the amino acid sequence depicted in FIG. 12 (SEQ ID NO:39);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 13 (SEQ ID NO:40);
n) the VH variant comprises the amino acid sequence depicted in FIG. 12 (SEQ ID NO:39);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 14 (SEQ ID NO:41);
o) the VH variant comprises the amino acid sequence depicted in FIG. 12 (SEQ ID NO:39);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 15 (SEQ ID NO:42);
or
p) the VH variant comprises rising the amino acid sequence depicted in FIG. 12 (SEQ ID NO:39);
and/or the Vk variant comprising the amino acid sequence depicted in FIG. 16 (SEQ ID NO:43).

29 more elements

Dependencies are inferred from the claim text.

Facts

Application

14/705,615Filed 6 May 2015 · continuation

Priority

18 Jan 2013

Published

US 2015/0050281 A120 Aug 2015

Granted

20 Sep 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 16/18
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against material from animals or humans
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
G01N 33/6896
Related to diseases not provided for elsewhere: neurological disorders, e.g. Alzheimer's disease
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies

Family

Application61/754,085Us provisional application · filed 18 Jan 2013

Application61/781,823Us provisional application · filed 14 Mar 2013

Application14/154,954Parent of this continuation · filed 14 Jan 2014

Application14/281,319Parent of this continuation · filed 19 May 2014

Application14/481,544Parent of this continuation · filed 9 Sep 2014

US 8,980,271 B2Parent of this continuation · filed 17 Mar 2015

US 8,980,270 B2Parent of this continuation · filed 17 Mar 2015

US 2015/0232544 A1Pre-grant publication · published 20 Aug 2015

US 9,051,367 B2Parent of this continuation

US 2014/0234214 A1Published application

US 2014/0294831 A1Published application

US 2015/0050281 A1Published application

US 9,447,180 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Claims27

Dependent claims

(i) VLCDR1 comprises the amino acid sequence of SEQ ID NO:1;
(ii) VLCDR2 comprises the amino acid sequence of SEQ ID NO:2;
and
(iii) VLCDR3 comprises the amino acid sequence of SEQ ID NO:3.

1 more element

An isolated nucleic acid comprising a nucleotide sequence encoding a VH variant and/or a Vk variant, wherein:

a) the VH variant comprises the amino acid sequence depicted in FIG. 9 (SEQ ID NO:36) and/or the Vk variant comprises the amino acid sequence depicted in FIG. 13 (SEQ ID NO:40);
b) the VH variant comprises the amino acid sequence depicted in FIG. 9 (SEQ ID NO:36);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 14 (SEQ ID NO:41);
c) the VH variant comprises the amino acid sequence depicted in FIG. 9 (SEQ ID NO:36);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 15 (SEQ ID NO:42);
d) the VH variant comprises the amino acid sequence depicted in FIG. 9 (SEQ ID NO:36);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 16 (SEQ ID NO:43);
e) the VH variant comprises the amino acid sequence depicted in FIG. 10 (SEQ ID NO:37);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 13 (SEQ ID NO:40);
f) the VH variant comprises the amino acid sequence depicted in FIG. 10 (SEQ ID NO:37);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 14 (SEQ ID NO:41);
g) the VH variant comprises the amino acid sequence depicted in FIG. 10 (SEQ ID NO:37);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 15 (SEQ ID NO:42);
h) the VH variant comprises the amino acid sequence depicted in FIG. 10 (SEQ ID NO:37);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 16 (SEQ ID NO:43);
i) the VH variant comprises the amino acid sequence depicted in FIG. 11 (SEQ ID NO:38);
and/or the Vk variant comprising the amino acid sequence depicted in FIG. 13 (SEQ ID NO:40);
j) the VH variant comprises the amino acid sequence depicted in FIG. 11 (SEQ ID NO:38);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 14 (SEQ ID NO:41);
k) the VH variant comprises the amino acid sequence depicted in FIG. 11 (SEQ ID NO:38);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 15 (SEQ ID NO:42);
l) the VH variant comprises the amino acid sequence depicted in FIG. 11 (SEQ ID NO:38);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 16 (SEQ ID NO:43);
m) the VH variant comprises the amino acid sequence depicted in FIG. 12 (SEQ ID NO:39);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 13 (SEQ ID NO:40);
n) the VH variant comprises the amino acid sequence depicted in FIG. 12 (SEQ ID NO:39);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 14 (SEQ ID NO:41);
o) the VH variant comprises the amino acid sequence depicted in FIG. 12 (SEQ ID NO:39);
and/or the Vk variant comprises the amino acid sequence depicted in FIG. 15 (SEQ ID NO:42);
or
p) the VH variant comprises rising the amino acid sequence depicted in FIG. 12 (SEQ ID NO:39);
and/or the Vk variant comprising the amino acid sequence depicted in FIG. 16 (SEQ ID NO:43).

29 more elements

Dependencies are inferred from the claim text.

Methods of treating a tauopathy

Life of this patent

Abstract

Claims27

Methods of treating a tauopathy

Life of this patent

Abstract

Claims27